These KAT6 inhibitors were shown to exhibit effective inhibition against both KAT6A and KAT6B, induce cellular senescence, and impede tumor growth in models of MYC‐driven lymphoma and AML [36]. This evidence concerns the gene KAT6A and acute myeloid leukemia.